

In the Claims

1 -13 (canceled).

14 (new). A composition of matter comprising:

- a) an isolated polypeptide comprising from 6 to 351 consecutive amino acids of SEQ ID NO: 437;
- b) an isolated polypeptide comprising the signal peptide sequence of SEQ ID NO: 437;
- c) an isolated polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 437;
- d) an isolated polypeptide comprising SEQ ID NO: 437; or
- e) an isolated polypeptide of a) through d) and a physiologically acceptable carrier.

15 (new). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising from 6 to 351 amino acids of SEQ ID NO: 437.

16 (new). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising the signal peptide sequence of SEQ ID NO: 437.

17 (new). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 437.

18 (new). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising SEQ ID NO: 437.

19 (new). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising SEQ ID NO: 437 and a pharmaceutically acceptable carrier.

20. (new). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 437 and a pharmaceutically acceptable carrier.

21 (new). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising the signal peptide sequence of SEQ ID NO: 437 and a pharmaceutically acceptable carrier.

22 (new). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising from 6 to 500 amino acids of SEQ ID NO: 437 and a pharmaceutically acceptable carrier.

23 (new-withdrawn). A method of making a polypeptide, said method comprising

- a) providing a population of host cells comprising a polynucleotide encoding a polypeptide according to claim 14;
- b) culturing said population of host cells under conditions conducive to the production of a polypeptide within said host cells; and
- c) purifying said polypeptide from said population of host cells.

24 (new-withdrawn). A method of binding a polypeptide of claim 14 to an antibody of comprising contacting said antibody with said polypeptide under conditions in which antibody can specifically bind to said polypeptide.